Fractyl Health
Fractyl Health Unveils Groundbreaking Preclinical Data on Rejuva®: A Revolutionary Single-Administration Gene Therapy for Diabetes at ASGCT 2025
BURLINGTON, Mass., April 28, 2025 — Fractyl Health, Inc. (Nasdaq: GUTS) is breaking new ground in tackling obesity and type ... Read more
Fractyl Health Intensifies Efforts on Innovative Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs: Key Clinical Milestones Expected in 2025
Fractyl Health is focusing on weight maintenance after GLP-1 withdrawal due to high demand from patients and doctors. The REMAIN-1 ... Read more
